VectorBuilder Gene Delivery Seminar

Oncolytic viruses offer a promising approach to cancer treatment, but their effectiveness can be limited by how tumor cells respond to viral infection. Understanding these responses and identifying biomarkers that influence viral activity could help overcome these challenges.

This seminar will discuss how tumor epigenetics can affect susceptibility to oncolytic viruses and how biomarker-driven viral engineering can help overcome antiviral barriers. Through research on malignant peripheral nerve sheath tumors (MPNSTs), this seminar will highlight how engineering oncolytic herpes simplex virus (HSV) can restore antitumor activity and support the development of more targeted viral therapies.